Corporate Ambition vs. Customer Needs: Uber, Disney, Novo Nordisk

The "Everything App" Delusion: Why Uber's Ambitious Strategy Risks Repeating Past Failures

This conversation reveals a critical, often-overlooked tension in business strategy: the chasm between what companies want and what customers need. While Uber, Disney, and Novo Nordisk grapple with their respective market positions, the discussion around Uber's "everything app" ambition highlights a recurring corporate delusion. The non-obvious implication is that even successful companies can stumble by prioritizing their own revenue goals over genuine customer behavior change. This analysis is crucial for investors and strategists who seek to identify durable competitive advantages, by understanding why seemingly logical expansion plans often falter, and how to distinguish between a company's vision and the market's reality. Those who grasp this distinction can gain an edge by avoiding overvalued companies chasing unproven strategies.

The Siren Song of the "Everything App"

The ambition for Uber to become an "everything app," a central hub for all mobility and travel needs, is a compelling narrative. It promises expanded revenue streams and deeper customer engagement. However, this vision clashes with a stark reality: customers rarely desire a single, all-encompassing platform. As Lou Whiteman points out, companies envision these monolithic apps to capture all revenue, but consumer behavior rarely shifts unless there's a significant, often economically ruinous, incentive. The comparison to PayPal, Meta's WhatsApp ambitions, and X (formerly Twitter) all underscore this point. These platforms, despite their logical appeal to the companies behind them, failed to fundamentally alter user habits.

"People don't want everything apps. Companies want everything apps because everything means we get all of the revenue, we can expand our business on the back of our customer base. I get that, but customers don't want that."

-- Lou Whiteman

The strategy hinges on changing deeply ingrained consumer behavior. While Uber's core ride-sharing and delivery businesses are strong, compelling users to book hotels or vacation rentals through Uber instead of established players like Booking.com or Expedia requires overcoming inertia and existing loyalty. Rachel Warren offers a counterpoint, citing the success of "super apps" like WeChat in China and Grab in Southeast Asia. These models, she argues, have proven successful in markets where consumers are accustomed to integrated digital experiences. However, she acknowledges that Western markets, where Uber primarily operates, have not historically shown the same appetite for such consolidated platforms. The challenge for Uber, then, is not simply offering new services, but creating a compelling enough value proposition--perhaps through loyalty programs like Uber One--to fundamentally alter how consumers plan and book their travel and daily needs.

The analogy to Costco is instructive here. Costco's profitability stems not from razor-thin margins on goods, but from annual membership fees. If Uber could replicate this model with Uber One, generating substantial profit from subscriptions rather than transaction fees, the economics could shift. However, Whiteman questions whether Uber can manage such a model with third-party services, especially when established players like Delta and Capital One already offer integrated travel booking. The core issue remains: changing consumer behavior is a monumental task, often underestimated by companies enamored with the potential for expanded revenue. The immediate success of Uber's shares, up 10% in early trading, suggests the market is buying the vision today, but the long-term viability hinges on whether this ambition translates into actual, sustained behavioral change.

Disney's Quiet Strength Amidst Market Skepticism

While Uber chases the elusive "everything app," Disney presents a different case: a company with a solid core business that the market seems reluctant to fully embrace. Despite strong Q1 2026 results, including record revenue and significant profit growth in its streaming division, Disney's stock has struggled, particularly over the past decade. Rachel Warren highlights the steady, consistent growth, with revenue up 7% year-over-year and operating income for Disney+ jumping 88%. The entertainment division also saw robust growth, even as the sports segment faces pressure from rising rights fees.

The company's strategy, under new CEO Josh D'Amaro, appears to be doubling down on its core strengths: experiences and intellectual property. D'Amaro's background in the experiences division, coupled with a focus on centralizing marketing and leveraging AI for personalization, signals a commitment to monetizing its fan base through theme parks, cruises, and other physical attractions. This focus on experiences, which already contributes significantly to profits, is presented as a safer long-term play than engaging in an endless content arms race with streaming competitors like Netflix.

"Leading into that experiences division, which already accounts for a lot of their overall profit, they're monetizing their fans multiple times. This is proving to be a really consistently profitable strategy, even in a difficult macro environment."

-- Rachel Warren

Lou Whiteman echoes this sentiment, noting that while the quarter was "perfectly fine" and represented the steady growth Disney needed after years of volatility, the market's lukewarm reaction is puzzling. He suggests that Disney's sprawling amalgamation of assets--legacy TV, sports, streaming, and experiences--might be too broad for investors to fully appreciate. The implication is that D'Amaro's tenure might involve strategic divestitures or partnerships, particularly in areas like sports and streaming, to allow for a sharper focus on the company's most profitable and defensible segments: experiences and IP. The current P/E multiple, under 15 forward, suggests the market is pricing in slower growth, but for long-term investors, the consistent profitability and growing experiences division offer a compelling case for ballast in a volatile market. The key question is whether Disney can strategically prune its less profitable ventures to unlock greater shareholder value.

Novo Nordisk's Volume Game: A Risky Bet on Price Cuts

Novo Nordisk, a company synonymous with the GLP-1 drug craze, finds itself in a precarious position. Despite strong sales growth, the stock has fallen significantly from its peak. Rachel Warren points to the oral version of Wegovy as a key driver, exceeding analyst expectations and capturing a significant share of the obesity market. This oral formulation, by lowering the barrier to entry, is tapping into a new patient segment. Overall sales are up 32% on a constant currency basis.

However, this volume-driven strategy comes at a cost: significant price cuts. Novo Nordisk is reducing prices by up to 70% in some channels, with list prices set to drop below $50 in 2027. This aggressive pricing strategy is concerning because the oral version of Wegovy requires substantially more of the active ingredient, semaglutide, than the injectable form. This means Novo is using more raw material to generate less profit per patient, directly impacting margins.

"So they're cutting prices by up to 70% in some channels. You've got list prices that are set to drop under $50 in 2027. But there's something I want to note here. The Wegovy pills require significantly more of the key active ingredient, semaglutide, to be effective compared to an injection. So what that means is Novo is using more raw material to make less profit per patient."

-- Rachel Warren

Lou Whiteman voices skepticism, likening the strategy to a familiar "making it up on volume" meme. He argues that Novo Nordisk is currently the "second best" in its core market, especially with Eli Lilly investing heavily in next-generation GLP-1s and other compelling pipeline candidates. Novo Nordisk's significant capital expenditures on new factories could become a liability if demand slows or competitive pressures intensify, leaving them with expensive, underutilized infrastructure. The company's pipeline, while strong in GLP-1 variations, lacks the diversification seen in competitors. This makes them vulnerable to becoming a "one-hit wonder" in the pharmaceutical industry, where patent cliffs and evolving market dynamics can quickly erode a dominant position. The impending patent expiration in the US in approximately five years adds another layer of urgency. While the stock saw a bounce, the underlying strategy of aggressive price cuts to drive volume, coupled with a less diversified pipeline, presents a significant long-term risk.

Key Action Items

• For Uber:
  • Immediate: Focus marketing and product development on enhancing the core ride-sharing and delivery experience, ensuring seamlessness and reliability.
  • Short-term (6-12 months): Conduct targeted A/B testing of bundled travel services (hotels, car rentals) with deeply discounted pricing or loyalty rewards to gauge genuine consumer adoption beyond novelty.
  • Long-term (18-24 months): If consumer adoption of ancillary services remains low, pivot resources from "everything app" expansion back to core business optimization and potentially explore strategic partnerships rather than direct integration.
• For Disney:
  • Immediate: Continue aggressive cost-cutting and operational efficiencies within the streaming and legacy TV segments.
  • Short-term (6-12 months): Explore strategic partnerships for the sports broadcasting rights and potentially some streaming content to reduce financial burden and focus capital.
  • Long-term (12-18 months): Double down on expanding capacity and enhancing the guest experience in parks and on cruise lines, leveraging IP for new attractions and themed experiences.
• For Novo Nordisk:
  • Immediate: Re-evaluate the aggressive pricing strategy for oral Wegovy, focusing on margin sustainability alongside volume.
  • Short-term (6-12 months): Accelerate investment in R&D for non-GLP-1 pipeline candidates to diversify the company's future revenue streams.
  • Long-term (12-18 months): Develop a clear strategy for navigating the upcoming US patent cliff for semaglutide, potentially through next-generation drug development or strategic acquisitions.
• General Investor Takeaway: Prioritize companies demonstrating durable competitive advantages rooted in genuine customer value, not just corporate ambition. Be wary of strategies that rely on massive shifts in consumer behavior without compelling, sustainable economic incentives.